Evaluation of Plasma Ghrelin, Omentin1 Levels and Insulin Resistance in Patients With Obstructive Sleep Apnea Syndrome

İngilizce (OpenAlex)

Objective: Available studies support the occurrence of a bidirectional association between obstructive sleep apnea syndrome (OSAS) and cardiovascular disorders. In this study, we aimed to evaluate the plasma ghrelin, omentin–1 levels, insulin resistance (IR) in patients with OSAS, and its cardiovascular consequences. Methods: This study was performed on 150 individuals who applied to the sleep laboratory with complaints such as snoring and sleep-breathing pause. Polysomnographic (PSG) evaluation was applied to every patient. Seventy-five individuals with Apnea-Hypopnea Index (AHI) ≥5 were diagnosed as OSAS and seventy-five individuals with AHI<5 were included as the without OSAS. Results: The median omentin-1 level was 59.0 ng/mL in the OSAS group and 105.0 ng/mL in without OSAS (p<0.001). The median ghrelin level in the OSAS group was 229.0 pg/ml and 180.0 pg/ml in the without OSAS group (p<0.001). The prevalence of OSAS was 2.667 times higher in males than females (OR=2.667). HOMA-IR scores were not different between OSAS and without OSAS groups (p=0.218). Patients with OSAS had higher BMI, neck circumference, and median ESS values compared to those without OSAS group (p<0.001). In obese, the risk of OSAS was found 3.058 times higher (OR= 3.058) (p<0.001). Conclusions: Median omentin-1 level was lower in the OSAS group than the without OSAS group, whereas median ghrelin level was higher in the OSAS and obese individuals. Due to the high prevalence of OSAS in hypertensive and obese individuals, effective screening, diagnosis, and treatment of OSAS are required to reduce cardiovascular risk.